In a major breakthrough for global HIV prevention efforts, the United States has approved the world’s first twice-yearly injection to prevent HIV infection, marking a pivotal step toward reducing new transmissions, especially among high-risk populations.
The long-acting drug, called lenacapavir, is developed by Gilead Sciences and has shown unprecedented success in clinical trials. Experts believe the shot could transform the fight against HIV, particularly for individuals who struggle with the burden of taking daily preventive pills.
“This really has the possibility of ending HIV transmission,” said Greg Millett, Director of Public Policy at amfAR, The Foundation for AIDS Research.
A Game-Changer for HIV Prevention
While the search for an effective HIV vaccine continues, many in the medical and public health community see lenacapavir as the most promising alternative to date. The injectable drug performed remarkably well in two major studies, virtually eliminating new infections in participants considered at high risk, far outperforming current oral Pre-Exposure Prophylaxis (PrEP) regimens.
Traditional PrEP, such as Truvada or Descovy, requires daily adherence to maintain effectiveness. However, adherence remains a major challenge for many users, leading to inconsistent protection. Lenacapavir’s biannual schedule could address that gap.
Global Impact Still Uncertain
Although U.S. approval marks an important milestone, questions remain about how widely the drug will be distributed both domestically and internationally. Access, affordability, and infrastructure are likely to shape how effective this new tool will be in real-world settings, particularly in low-income regions where HIV rates remain high.
Global health advocates are now calling on Gilead and international organisations to ensure equitable access to the shot. Without widespread availability, experts warn that the benefits of this breakthrough could be limited to wealthier nations or populations with strong healthcare systems.
A Step Closer to Ending HIV?
Condoms and daily PrEP will continue to play a crucial role in HIV prevention, but lenacapavir could offer a more convenient, discreet, and effective option for millions. Public health leaders view the shot as a significant opportunity to curb the virus, especially in communities where stigma, poverty, or lack of resources hinder regular treatment and prevention.
For now, the world watches as the rollout begins with hopes that lenacapavir’s promise will extend far beyond U.S. borders and into the communities that need it most.
